A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients With Spinal Muscular Atrophy
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Reldesemtiv (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Sponsors Cytokinetics
- 06 May 2021 According to a Cytokinetics media release, a manuscript on this study was published in Neurotherapeutics.
- 05 Oct 2018 According to an Astellas Pharma media release, additional data were presented at the 2018 Muscle Study Group Scientific Meeting.
- 05 Oct 2018 Results presented in an Astellas Pharma Media Release.